ARTICLE | Clinical News
EPI-HNE-4: Phase Ib
January 29, 2001 8:00 AM UTC
DYAX said that in a European Phase Ib trial in 12 volunteers run by partner Debiopharm S.A. (Lausanne, Switzerland), EPI-HNE-4 was well tolerated at two dosages tested. DYAX also said that bronchoalv...